Lisata Therapeutics (LSTA) vs SciSparc (SPRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Lisata Therapeutics is the larger company by market cap ($647,451 vs $481,603), about 1.3 times the size, while SciSparc is growing revenue faster (-54.6% vs -83.0%). SciSparc converts more of its revenue into profit, with a net margin of -481.2% versus -9756.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LSTA | SPRC |
|---|---|---|
| Share price | $0.8989 | $0.1955 |
| Market cap | $647.45K | $481.60K |
| 1-day change | -1.22% | -34.83% |
| YTD return | -51.67% | — |
| 1-year return | -54.14% | — |
| 5-year return | -93.89% | — |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-28.20 | $248.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $170.00K | $1.31M |
| Revenue growth (YoY) | -83.00% | -54.64% |
| Net income (latest FY) | $-16.59M | $-6.28M |
| Gross margin | — | 38.74% |
| Operating margin | -10711.18% | -560.18% |
| Net margin | -9756.47% | -481.16% |
| 52-week high | $76.05 | $29.88 |
| 52-week low | $0.85 | $0.167 |
| Distance from 52-week high | -98.82% | -99.35% |
| Analyst consensus | none | — |
| Average volume | 13.46K | 2.93M |
| Shares outstanding | 720.27K | 2.46M |
| Employees | 21 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SciSparc is more profitable, keeping -481.2 cents of every revenue dollar as net income versus -9756.5 cents for Lisata Therapeutics.
- SciSparc grew revenue faster in its latest fiscal year (-54.64% vs -83.00%).
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About SciSparc
SPRC stock →SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
LSTA vs SPRC FAQ
Which is bigger, Lisata Therapeutics or SciSparc?
Lisata Therapeutics (LSTA) is larger, with a market capitalization of $647.45K compared with $481.60K for SciSparc (SPRC).
Are Lisata Therapeutics and SciSparc in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.